RedHill Biopharma Secures $6 Million in Private Placement

The offering involved the sale of 8,571,429 American Depositary Shares at a combined price of $0.70 per share, alongside accompanying Series A-1 and A-2 warrants. While the upfront $6 million bolsters the company’s near-term balance sheet, the additional $13.4 million remains contingent on the full cash exercise of these warrants. H.C. Wainwright & Co. served as the exclusive placement agent for the transaction.

Management intends to deploy the capital to expand its commercial portfolio through strategic acquisitions. Although the company has signaled an intent to hunt for revenue-generating products to complement its existing gastrointestinal and infectious disease pipeline, no definitive agreements have been signed. The transaction remains subject to customary closing conditions and market variables.